Northwest Biotherapeutics Inc (QB) (NWBO) Share Price

500,000 shares traded in first few minutes and bigger blocks on both sides.

Well that was a rough start to the week.

Why don't you use your old alias QL300. Do you want to have another bet with me? That move down to .39 was not as impossible as you thought. You forgot this is dilution dilution dilution company. I'll put this alias away too.

Yea sure . NWBO will actually design and finish a trial in 1 year . Everyone believes that .
And of course they won't take another several years to actually file for approval . 

Did you read the news about LUM-299 and Daiichi?

The collaborator that LP chose among many parties will bring a big check and LP doesn't need the money from the lawsuit.

Take a look at the outcome measures adopted in the combo trial. No trials will take two or three years. With all the data that NWBO has, the OS can be predicted simply by GSVA score of a certain gene sets as shown in the Nature paper.

February 2nd will be the 20 Year Anniversary of this board!!! LP should be celebrating.

Two days left in the year. Not expecting any news unfortunately. So, hopefully tax loss selling is done. Any warrant conversion/sales are done. Dilution discount sales done. So, at least the pressure on PPS may be gone for a few weeks?

Hello. ICLIGHT, the post is relative to NWBO. You need to have another cup of coffee.

Your desperation is spiking now.

Did I tell you one year ago: bail now or cry later?

Time to cry now.

I don't think the settlement will be huge in $10's Billion. The MMS will fight to the nail. But I think it would be north of $1 Billion among 7 bad characters. This will give NWBO ample of money to move forward in all directions. Remember from the latest 10Q, NWBO has decided to have tumor shrinkage as a primary end point compare to OS at 5 years. This means they can do couple of trials and in less than 2-3 years they have the results we all looking for. Now you should ask yourself how much $ BP will put forward to buy NWBO.

Barnstormer, The lawsuit is specifically is requesting a trial by jury. Timing of The settlement is in the hands of the Market Makers (Defendants). The Market Makers will not want to go through depositions.

Everything is relevant. Ask Fraudstein if it is relevant.

Filling the missing gaps is included in what I am talking about. Obviously pivoting on the media strategy (to include both traditional and social media) would involve being a lot more transparent and clear-cut in answering the types of questions you are asking instead of opaque and vague.

I did not mention it but quarterly conference calls (though maybe these could be regarded as kind of antiquated too) would be an appropriate place to answer questions of the nature you are discussing and it would be a really good bonus if 2025 were the year NWBO started being more transparent in this way. I say bonus because when it comes to actually trying to improve our share price, NWBO could probably get away with just being a whole lot more proactive on the media front without having to subject themselves to quarterly conference calls just yet.

Irrelevant. This board is for NWBO. Are you lost, little boy? Where's your mommy?

Why do you always post irrelevant crap? You run out of spin for why the P3 has gone nowhere after you hyping approval in 2024?

I've had almost 5 years to review my position. If we don't have approval by end of H2 '25, my thesis was wrong and I must walk.

It would be tragic to end up a perpetual board whiner.

I have enough of your endless negative comments, one after the other like machine gun fire, you go on ignore!

What's your purpose here my good man? Investor like me, or?

Despite my negative view of the management, I still believe in the science, and I am very excited to see what happens after approval.

She is an asshat, not a genius. You need to look up that word. She has crushed SH.

You people act likes it's 1985 and institutional investors and BP need to "find out" about small biotechs. They have teams of researchers, statisticians, and oncologists with drug approval experience that are well aware of all small biotechs even ones on the OTC.

NWBO isn't a secret. There is simply no potential based on the trial that has been running for 10+ years with massaged data to fit a very questionable new trial protocol that the company was not even confident enough to submit to the FDA.

A good review of their extended history and your outlook will change. A company that always complains, come up with excuses and do not take matters in their own hands will never succeed.

Watch the excuses flow again in Q1/Q2 when the share price continues to be hammered after a brief spike at UK approval news.

Agreed. The same set of folks were expecting MTD denial in late 2023, then first half of 2024, and so on. Don't expect anything to change in 2025 either. The MMs will delay and fight till the bitter end. Probably another couple of years before we see light at the end of the tunnel.

I don't share your dismal outlook for NWBO, but best of luck to you.

Agree
He should share with us that "libation" , so rest of us can feel liberated as well 

Fully diluted and counting all securities as shares, we are at about 1.8 billion shares. How did you get to that calculation?
There are now 1.3B O/S. Additionally, NWBO management and some staff + C shares sold 1.6 Billion. So how did you get to 1.8?

A sign there is no end in sight. Dilution is going to be endless. But continue to blame it on shorts. Why tie management to stock performance?

Folks posting they bought shares here and on social media, etc are all signs they want more bag holders so they can get out at the next pump. And that 2025 is expected to be another lost year (outside a brief UK approval spike).

XMaster, quick is relative. You are dealing with attorneys, judges and court schedules. The case is unlikely to settle, regardless of MM desires, if NWBO feels the chance of it prevailing is high enough. While unlikely IMO, the company could decide to take a chance with a jury. Tens of billions? With all respect, suspect you may have gotten into the New Years libations a couple of days early.

10s of billions 
Don't know if you are pumping or is this a delusion that you actually believe .

That has to be a dupe account for CO.

Lol! The more we have such pumpers you know this company ain't going nowhere!!! ;)

By the way, there are several delusional posters (or pumpers) who thinks or wants naive retail to believe this is a trillion dollar company. They don’t realize that the company has to reach and stay at $2-3B valuation first.

No, but now it seems to hit a new crescendo on a regular basis.

I thought I had let the wait get to me, but every morning I log in to see evidence that it can get much worse.

You're just figuring that out ? :)

You love talking both ways! You didn't take my bet and I gave you until end of June 2025, so everyone here (except pumpers and your colleagues) knows that you don't expect non dilutive cash.

My bet is still open, Flip. Put your word where your mouth is!

and go into the 10’s of billions

Settle for 10's of billions of dollars?

This is a mad house.

#DDAmanda Chart on $NWBO:

#DDAmanda #XMAS Special Signup:

https://ddamanda.com/SignUpXMAS.php



Z

So how many years ago did Duffy come when among others I believe you also were saying that he is there to seal the deal for Merck or some such things . 

If they want to settle and they can keep the money fore another year , why would they want to give it away right away . That's just how real world works . They will delay it till there is no other resort . That is based on assumption that MTD is denied . 
There will be lots of motions to and fro regarding discovery before it even begins and before they reach the point that they actually have to give any meaningful documents . You must have gotten some understanding by now that how long does it take to rule on each motion and then other party's right to reply to a motion etc etc . 

Have to admit LP looks like a genius justwith the new financing compared to Geert at Cel Sci . He really just screwed shareholders it looks like with the new cash raise at.31 .wow.

You have a screw loose. I did not say there was or wasn’t. You’ve been saying I said there was, and now you are saying I’ve been saying there isn’t.

I don’t know if there will be upfront cash, or some other nondilutive funding, but you repeatedly say there will not be any in the first quarter.

Here’s my response:

1. Oncovir

2. Trial will not get off the ground in 2025 except for registration and paperwork to keep retail on the hook because there is no money to pay for it. Most grant applications take 6-9 months before they are funded. But first and foremost, you have to write a grant application, and that itself takes a month or two. Then there is about 10% chance to get the funding. Regarding UK, there will be no reimbursement support in 2025. Total revenue in 2025 to be less than $12-15M (less than their burn rate for one quarter). Expect a ton of dilution in 2025 and 2026.

3. Flaskworks commercial approval is not expected in 2025. Very likely for at least another 18 months and that too if everything goes well.

4. You are asking too much from LP. Either stay a bag holder or sell and move on!

Lol, if history is any judge expect more excuses and complaining. But no media blitz. Everyone in the universe is paid by and compromised by KG, so why bother?

Just some publications from Dr. Lisa Butterfield, a world-renowned scientist on DC vaccine. The following are just for illustration purpose. There are more papers that she coauthored with Andres Salazar or acknowledged him.

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma
Sabine Mueller,1,2,3,4 Jared M. Taitt,2 Javier E. Villanueva-Meyer,5 Erin R. Bonner,6 Takahide Nejo,2 Rishi R. Lulla,7 Stewart Goldman,8 Anu Banerjee,2,3 Susan N. Chi,9 Nicholas S. Whipple,10 John R. Crawford,11 Karen Gauvain,12 Kellie J. Nazemi,13 Payal B. Watchmaker,2 Neil D. Almeida,14 Kaori Okada,2 Andres M. Salazar,15 Ryan D. Gilbert,2 Javad Nazarian,4,6 Annette M. Molinaro,2 Lisa H. Butterfield,16,17 Michael D. Prados,2,3 and Hideho Okada2,16,18

https://www.jci.org/articles/view/140378

559 Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 PORTER platform trial in metastatic castration-resistant prostate cancer patients
Kristin Shotts1, Timothy Howes1, Jia Yu1, Julie Densmore1, Diane Da Silva1, Dinesh Kumar1, Sandra Santulli-Marotto1, Christopher Cabanski1, Elaine Eisenbeisz1, Geoffrey Ivison2, Aaron Mayer2, Jonni Moore3, Derek Jones3, Kimberly Kraynyak4, Alex Dolgoter4, Richard Chen5, Lisa Butterfield1, Theresa LaVallee1, Samantha Bucktrout1, Lacey Padron1, Ute Dugan1, Michael Yellin6, Tibor Keler6, Jill O'Donnell-Tormey7, Justin Fairchild1, Lisa Salvador8, Kristopher Wentzel9, Lawrence Fong10, Sumit Subudhi11, Nina Bhardwaj12, Karen Autio13 and Matthew Galsky12

Acknowledgements We extend our gratitude to the patients, their families, the clinical investigators, and their site staff members who are making this trial possible. We would also like to thank Carri Browne, Christopher Perry, and Lancelote Leong at Parker Institute for Cancer Immunotherapy (PICI) for operations leadership of the trial. We thank Maria Jaimes and Quentin Low from Cytek Biosciences for spectral flow method development and sample analysis. We thank Jay Campbell (CRI), Samik Upadhaya (CRI), Andres Salazar (Oncovir) and Silvia Boffo (BMS) for their contributions. We thank Bristol Myers Squibb (BMS), Celldex, Oncovir and Inovio for collaboration and study drugs. The study was funded by Cancer Research Institute, BMS and PICI.


https://jitc.bmj.com/content/10/Suppl_2/A585

Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With a-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

Authors: Hideho Okada okadah@upmc.edu, Pawel Kalinski, Ryo Ueda, Aki Hoji, Gary Kohanbash, Teresa E. Donegan, Arlan H. Mintz, Johnathan A. Engh, David L. Bartlett, Charles K. Brown, Herbert Zeh, Matthew P. Holtzman, Todd A. Reinhart, Theresa L. Whiteside, Lisa H. Butterfield, Ronald L. Hamilton, Douglas M. Potter, Ian F. Pollack, Andres M. Salazar, and Frank S. Lieberman

https://ascopubs.org/doi/full/10.1200/JCO.2010.30.7744

Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC

Hideho Okada; Lisa H. Butterfield; Ronald L. Hamilton; Aki Hoji; Masashi Sakaki; Brian J. Ahn; Gary Kohanbash; Jan Drappatz; Johnathan Engh; Nduka Amankulor; Mark O. Lively; Michael D. Chan; Andres M. Salazar; Edward G. Shaw; Douglas M. Potter; Frank S. Lieberman

https://aacrjournals.org/clincancerres/article/21/2/286/245329/Induction-of-Robust-Type-I-CD8-T-cell-Responses-in


Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study

Ian F. Pollack, Regina I. Jakacki, Lisa H. Butterfield, Ronald L. Hamilton, Ashok Panigrahy, Daniel P. Normolle, Angela K. Connelly, Sharon Dibridge, Gary Mason, Theresa L. Whiteside & Hideho Okada

Acknowledgments

UPCI Clinical Research Services for regulatory management, Andres Salazar, Oncovir, Inc., for provision of poly-ICLC, physicians who referred their patients, and the patients and families who participated in this trial.


https://link.springer.com/article/10.1007/s11060-016-2245-3

And yet Flipper doesn’t think there will be upfront non dilutive cash before end of June 2025! ;)

The settlement will be quick and go into the 10’s of billions as the MM would never allow the case to end in the hands of a jury.

Lisa Butterfield
Distinguished Scientist at Merck
I am a Distinguished Scientist at Merck, in Discovery Oncology in South San Francisco. My research has been focused on cancer vaccines, immune profiling and cellular therapies for melanoma, hepatocellular cancer and other tumor types. I was most recently Vice President, Research and Development at the Parker Institute for Cancer Immunotherapy, where I supported cell therapy initiatives and clinical trial biospecimen and biomarker projects as well as an Adjunct Professor of



https://nwbio.com/nw-bio-announces-scientific-advisory-board/
Dr. Samir N. Khleif

Dr. Khleif is the Director of the Georgia Cancer Center, the State cancer center of Georgia at Augusta University. He is a Georgia Research Alliance Distinguished Cancer Scientist and Clinician, and a professor of Medicine, Biochemistry, Cancer Biology and Graduate Studies. He also serves as the Director of the Immuno-Oncology and Immunetherapeutics Program. Dr. Khleif previously served as Chief of the Cancer Vaccine Section at the National Cancer Institute (NCI), and Professor of Medicine at Uniformed Services University of the Health Sciences. He also served as a Special Assistant to the FDA Commissioner from 2006-2009, where he led the FDA Critical Path for Oncology designed to restructure the oncology drug development process.

Between 0 and 100 days.

In case, the longs still have doubt. Note that for the first five years the research project used Nivolumab which was replaced with Pembrolizumab starting in 2022. Merck pushed BMS out of the poject?

2024
https://reporter.nih.gov/search/xkk-VGQ1UUOqhb8O81ygjA/project-details/10906762

2023
https://reporter.nih.gov/search/nIYnpxNtzUu9Ey0NkNdBqA/project-details/10673749

2022
https://reporter.nih.gov/search/nIYnpxNtzUu9Ey0NkNdBqA/project-details/10496439

2021
https://reporter.nih.gov/search/8BIQlZadTUm8eOduhRzk9A/project-details/10225550

2020
https://reporter.nih.gov/search/8BIQlZadTUm8eOduhRzk9A/project-details/9983047

2019
https://reporter.nih.gov/search/uNeRxUSW0UeV4frdTW_JQg/project-details/9752974

2018
https://reporter.nih.gov/search/uNeRxUSW0UeV4frdTW_JQg/project-details/9543452

2017
https://reporter.nih.gov/search/uNeRxUSW0UeV4frdTW_JQg/project-details/9357417

PROJECT SUMMARY/ABSTRACT – Project 1 The lack of effective treatments for glioblastoma (GBM) patients remains a significant health problem and highlights the need for novel and innovative approaches. Immunotherapy is an appealing strategy because of the potential ability for immune cells to traffic to and destroy infiltrating tumor cells in the brain. For the past 15 years, our group and others have been testing active vaccination strategies, such as dendritic cells (DC) pulsed with tumor lysate, to induce antitumor immunity in glioblastoma patients. From the interim results of the clinical trial we initiated in our current SPORE funding period, we found that in addition to inducing T-cell infiltration into brain tumors, DC vaccination + anti-PD1 blockade may also create a pro-inflammatory environment within the tumor that induces the immigration of immunosuppressive myeloid cells (TIM). These cells are phenotypically similar to the myeloid cells that dominantly attenuate the T-cell response to chronic viral infections, and may counteract the effective anti-tumor T-cell responses induced by DC vaccination within the tumor microenvironment. Therapies that target myeloid cells within the tumor microenvironment represent a promising new strategy. As such, inhibition of these myeloid cells using a CSF-1R inhibitor, in conjunction with autologous tumor lysate-pulsed DC vaccination (ATL-DC) and PD-1 mAb blockade, resulted in significantly prolonged survival in tumor-bearing animals with large, well-established intracranial (i.c.) gliomas. Our hypothesis is that myeloid cells mediate adaptive immune resistance in response to T cell activation induced by immunotherapy. In this SPORE Project renewal, we have planned a series of novel pre-clinical studies to re- polarize myeloid cells, to optimize how the timing and sequence of immunotherapy can influence ant-tumor immunity, and a new clinical trial to test the first-in-human combination of a new brain penetrant CSF-1R inhibitor (CSF-1Ri; PLX3397, Daiichi-Sankyo) with DC vaccination and PD-1 mAb blockade (Pembrolizumab, Merck) in patients with newly diagnosed GBM. A better understanding of the biology of these cellular interactions will provide insight into more effective ways to induce therapeutic anti-tumor immune responses for this deadly type of brain tumor. These studies span the continuum of translational research in brain tumor immunotherapy, and will likely provided informative new insights for the development of new, rational immune-based strategies for brain tumor patients.

819 Temporal influence of PD-1 blockade after vaccination on macrophage-driven CD8+ T cell exhaustion within the glioblastoma microenvironment
https://jitc.bmj.com/content/12/Suppl_2/A927

Conclusions This study reveals that timing may impact how ATL-DC and aPD1 combined therapies can alter the immune landscape of GBM and highlights tumor-associated macrophages as a major obstacle to clinical benefit. Future strategies targeting these populations or blocking their immunosuppressive interactions with anti-tumor CD8+ T cells hold promise for improving the efficacy of immunotherapies in GBM.

Midland a great spot, but Odessa's more fun.A lot of my older Midland buds are no longer with us like Bobby Holt.....!BUT, the spirit of Midland lives on forever. AND Landman's a good show, but a bit sketchy on reality. The Permian that exists today doesn't need "Pump Jacks"!:):):) But who cares about the minor stuff. What is truly great about the show is that about every other line that comes out of Billy Bob's mouth is a quote for some occasion.

Cheers,

BB

MM are also highly concerned the definition of spoofing will be uncomfortably broader than prior cases if NWBO’s case moves forward. So if MTD denied, there is more incentive for defendants to settle before a written MTD recommendation is made.

And it's their (nw) choice to use or not (need to use) the 50m from this fund :)

Yes, negotiations are typically not tipped prior to completion. If there is an agreement, it is still awaiting something for signature.